Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma
Qin Tang , Guanghui Hu , Ye Sang , Yulu Chen , Guangyan Wei , Meiyan Zhu , Mengke Chen , Shiyong Li , Rengyun Liu , Zhenwei Peng
Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (5) : e1703
Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma
• TERT promoter mutation confers sensitivity to PLK1 inhibitors in HCC. • The selective growth inhibition of TERT mutant HCC cells induced by PLK1 inhibitor was mediated by Smad3. • Combined inhibition of PLK1 and Smad3 showed a cooperative anti-tumor effect in TERT mutant HCC cells.
hepatocellular carcinoma / PLK1 / Smad3 / TERT promoter mutation
2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
/
| 〈 |
|
〉 |
PDF
